PULMONX CORPORATION Research and Development Expense
PULMONX CORPORATION (LUNG) reported Research and Development Expense of $5.03 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-04
- PULMONX CORPORATION research and development expense for the quarter ending 2026-06-30 was $5.03M, a 5.13% decline year-over-year.
- PULMONX CORPORATION research and development expense for the quarter ending 2026-03-31 was $4.90M, a 3.01% increase year-over-year.
- PULMONX CORPORATION research and development expense for the quarter ending 2025-12-31 was $4.58M, a 14.55% increase year-over-year.
- PULMONX CORPORATION research and development expense for the quarter ending 2025-09-30 was $4.85M, a 29.43% increase year-over-year.
- PULMONX CORPORATION research and development expense for fiscal 2025 was $19.49M, a 10.93% increase from fiscal 2024.
- PULMONX CORPORATION research and development expense for fiscal 2024 was $17.57M, a 2.82% decline from fiscal 2023.
- PULMONX CORPORATION research and development expense for fiscal 2023 was $18.08M, a 17.43% increase from fiscal 2022.
- PULMONX CORPORATION research and development expense for fiscal 2022 was $15.40M, a 17.87% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.03M 10-Q · filed 2026-08-04 | $9.93M 10-Q · filed 2026-08-04 | $14.52M derived: sum of 3 quarters · filed 2026-08-04 | $19.36M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $4.90M 10-Q · filed 2026-05-04 | $9.48M derived: sum of 2 quarters · filed 2026-05-04 | $14.33M derived: sum of 3 quarters · filed 2026-05-04 | $19.63M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $9.43M derived: sum of 2 quarters · filed 2026-03-10 | $14.73M derived: sum of 3 quarters · filed 2026-08-04 | $19.49M 10-K · filed 2026-03-10 |
| 2025-09-30 | $4.85M 10-Q · filed 2025-11-12 | $10.15M derived: sum of 2 quarters · filed 2026-08-04 | $14.91M 10-Q · filed 2025-11-12 | $18.91M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $5.31M 10-Q · filed 2026-08-04 | $10.06M 10-Q · filed 2026-08-04 | $14.06M derived: sum of 3 quarters · filed 2026-08-04 | $17.81M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $4.76M 10-Q · filed 2026-05-04 | $8.76M derived: sum of 2 quarters · filed 2026-05-04 | $12.50M derived: sum of 3 quarters · filed 2026-05-04 | $18.12M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $7.75M derived: sum of 2 quarters · filed 2026-03-10 | $13.36M derived: sum of 3 quarters · filed 2026-03-10 | $17.57M 10-K · filed 2026-03-10 |
| 2024-09-30 | $3.74M 10-Q · filed 2025-11-12 | $9.36M derived: sum of 2 quarters · filed 2025-11-12 | $13.57M 10-Q · filed 2025-11-12 | $17.46M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $5.62M 10-Q · filed 2025-08-01 | $9.82M 10-Q · filed 2025-08-01 | $13.72M derived: sum of 3 quarters · filed 2025-08-01 | $17.94M derived: sum of 4 quarters · filed 2025-08-01 |
| 2024-03-31 | $4.21M 10-Q · filed 2025-05-02 | $8.11M derived: sum of 2 quarters · filed 2025-05-02 | $12.33M derived: sum of 3 quarters · filed 2025-05-02 | $18.04M derived: sum of 4 quarters · filed 2025-05-02 |
| 2023-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $8.12M derived: sum of 2 quarters · filed 2025-02-25 | $13.83M derived: sum of 3 quarters · filed 2025-02-25 | $18.08M 10-K · filed 2025-02-25 |
| 2023-09-30 | $4.22M 10-Q · filed 2024-11-01 | $9.93M derived: sum of 2 quarters · filed 2024-11-01 | $14.18M 10-Q · filed 2024-11-01 | $18.09M derived: sum of 4 quarters · filed 2024-11-01 |
| 2023-06-30 | $5.71M 10-Q · filed 2024-08-02 | $9.96M 10-Q · filed 2024-08-02 | $13.87M derived: sum of 3 quarters · filed 2024-08-02 | $18.23M derived: sum of 4 quarters · filed 2024-08-02 |
| 2023-03-31 | $4.25M 10-Q · filed 2024-05-03 | $8.16M derived: sum of 2 quarters · filed 2024-05-03 | $12.52M derived: sum of 3 quarters · filed 2024-05-03 | $16.12M derived: sum of 4 quarters · filed 2024-05-03 |
| 2022-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $8.27M derived: sum of 2 quarters · filed 2024-02-27 | $11.86M derived: sum of 3 quarters · filed 2024-02-27 | $15.40M 10-K · filed 2024-02-27 |
| 2022-09-30 | $4.37M 10-Q · filed 2023-11-03 | $7.96M derived: sum of 2 quarters · filed 2023-11-03 | $11.49M 10-Q · filed 2023-11-03 | $15.20M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | $3.59M 10-Q · filed 2023-08-04 | $7.13M 10-Q · filed 2023-08-04 | $10.84M derived: sum of 3 quarters · filed 2023-08-04 | $13.65M derived: sum of 4 quarters · filed 2023-08-04 |
| 2022-03-31 | $3.53M 10-Q · filed 2023-05-08 | $7.24M derived: sum of 2 quarters · filed 2023-05-08 | $10.06M derived: sum of 3 quarters · filed 2023-05-08 | $13.56M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | $3.71M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $6.52M derived: sum of 2 quarters · filed 2023-03-01 | $10.03M derived: sum of 3 quarters · filed 2023-03-01 | $13.06M 10-K · filed 2023-03-01 |
| 2021-09-30 | $2.81M 10-Q · filed 2022-11-08 | $6.32M derived: sum of 2 quarters · filed 2022-11-08 | $9.36M 10-Q · filed 2022-11-08 | $11.83M derived: sum of 4 quarters · filed 2022-11-08 |
| 2021-06-30 | $3.51M 10-Q · filed 2022-08-08 | $6.54M 10-Q · filed 2022-08-08 | $9.01M derived: sum of 3 quarters · filed 2022-08-08 | $11.01M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $3.03M 10-Q · filed 2022-05-09 | $5.51M derived: sum of 2 quarters · filed 2022-05-09 | $7.50M derived: sum of 3 quarters · filed 2022-05-09 | $8.93M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $2.47M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $4.47M derived: sum of 2 quarters · filed 2022-03-01 | $5.89M derived: sum of 3 quarters · filed 2022-03-01 | $7.46M 10-K · filed 2022-03-01 |
| 2020-09-30 | $2.00M 10-Q · filed 2021-11-09 | $3.42M derived: sum of 2 quarters · filed 2021-11-09 | $4.99M 10-Q · filed 2021-11-09 | $6.59M derived: sum of 4 quarters · filed 2021-11-09 |
| 2020-06-30 | $1.43M 10-Q · filed 2021-08-10 | $2.99M 10-Q · filed 2021-08-10 | $4.59M derived: sum of 3 quarters · filed 2021-08-10 | $5.99M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $1.56M 10-Q · filed 2021-05-12 | $3.17M derived: sum of 2 quarters · filed 2021-05-12 | $4.57M derived: sum of 3 quarters · filed 2021-05-12 | |
| 2019-12-31 | $1.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $3.00M derived: sum of 2 quarters · filed 2021-03-15 | $6.05M 10-K · filed 2021-03-15 | |
| 2019-09-30 | $1.40M 10-Q · filed 2020-11-13 | $4.45M 10-Q · filed 2020-11-13 | ||
| 2018-12-31 | $6.99M 10-K · filed 2021-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 | |
| TELA Bio, Inc. (TELA) | United States | $0.057B | -0.82 |
| Xtant Medical Holdings, Inc. (XTNT) | United States | $0.053B | |
| Spectral AI, Inc. (MDAI) | United States | $0.052B |